IL146697A0 - SELECTIVE iGluR5 RECEPTOR FOR THE TREATMENT OF MIGRAINE - Google Patents

SELECTIVE iGluR5 RECEPTOR FOR THE TREATMENT OF MIGRAINE

Info

Publication number
IL146697A0
IL146697A0 IL14669700A IL14669700A IL146697A0 IL 146697 A0 IL146697 A0 IL 146697A0 IL 14669700 A IL14669700 A IL 14669700A IL 14669700 A IL14669700 A IL 14669700A IL 146697 A0 IL146697 A0 IL 146697A0
Authority
IL
Israel
Prior art keywords
migraine
treatment
iglur5 receptor
selective iglur5
selective
Prior art date
Application number
IL14669700A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL146697A0 publication Critical patent/IL146697A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14669700A 1999-07-06 2000-06-27 SELECTIVE iGluR5 RECEPTOR FOR THE TREATMENT OF MIGRAINE IL146697A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27
PCT/US2000/016297 WO2001001972A2 (en) 1999-07-06 2000-06-27 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Publications (1)

Publication Number Publication Date
IL146697A0 true IL146697A0 (en) 2002-07-25

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14669700A IL146697A0 (en) 1999-07-06 2000-06-27 SELECTIVE iGluR5 RECEPTOR FOR THE TREATMENT OF MIGRAINE

Country Status (28)

Country Link
US (4) US6566370B1 (https=)
EP (1) EP1200073B1 (https=)
JP (1) JP4619595B2 (https=)
KR (1) KR20020024300A (https=)
CN (1) CN1230174C (https=)
AR (1) AR029373A1 (https=)
AU (1) AU773304B2 (https=)
BR (1) BR0012175A (https=)
CA (1) CA2378613C (https=)
CZ (1) CZ20014488A3 (https=)
DE (1) DE60032905T2 (https=)
DK (1) DK1200073T3 (https=)
DZ (1) DZ3209A1 (https=)
EA (1) EA004290B1 (https=)
ES (1) ES2278619T3 (https=)
HK (1) HK1047036A1 (https=)
HR (1) HRP20020013A2 (https=)
HU (1) HUP0202253A3 (https=)
IL (1) IL146697A0 (https=)
MX (1) MXPA01012726A (https=)
MY (1) MY133503A (https=)
NO (1) NO20016246L (https=)
NZ (1) NZ515616A (https=)
PE (1) PE20010299A1 (https=)
PT (1) PT1200073E (https=)
SK (1) SK112002A3 (https=)
TR (1) TR200200066T2 (https=)
WO (1) WO2001001972A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2574801A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
AU2002227020A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
EA200300770A1 (ru) * 2001-01-05 2003-10-30 Эли Лилли Энд Компани Антагонисты рецепторов возбуждающей аминокислоты
AU2002228736A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
EP1511741B1 (en) 2002-04-26 2012-12-26 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
SG174095A1 (en) 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CN101578259A (zh) 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
US10591492B2 (en) 2018-03-05 2020-03-17 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
MX2022005490A (es) 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
US11957675B2 (en) 2021-02-09 2024-04-16 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
EA199900912A1 (ru) * 1997-04-07 2000-04-24 Эли Лилли Энд Компани Фармацевтические средства
ATE240299T1 (de) * 1999-07-06 2003-05-15 Lilly Co Eli Diester prodrugs von decahydroischinoline-3- carbonsäure

Also Published As

Publication number Publication date
NO20016246L (no) 2002-03-04
WO2001001972A2 (en) 2001-01-11
KR20020024300A (ko) 2002-03-29
EP1200073B1 (en) 2007-01-10
HUP0202253A2 (hu) 2002-11-28
US7157582B2 (en) 2007-01-02
EA004290B1 (ru) 2004-02-26
NO20016246D0 (no) 2001-12-19
CA2378613C (en) 2007-10-02
US6855823B2 (en) 2005-02-15
WO2001001972A3 (en) 2001-12-06
ES2278619T3 (es) 2007-08-16
CN1359289A (zh) 2002-07-17
PT1200073E (pt) 2007-03-30
MXPA01012726A (es) 2002-07-02
JP4619595B2 (ja) 2011-01-26
AR029373A1 (es) 2003-06-25
US6759418B2 (en) 2004-07-06
EA200200132A1 (ru) 2002-06-27
DK1200073T3 (da) 2007-05-07
EP1200073A2 (en) 2002-05-02
DZ3209A1 (fr) 2001-01-11
HK1047036A1 (zh) 2003-02-07
AU5873200A (en) 2001-01-22
BR0012175A (pt) 2002-03-05
DE60032905T2 (de) 2007-10-18
US20030199546A1 (en) 2003-10-23
CN1230174C (zh) 2005-12-07
CA2378613A1 (en) 2001-01-11
HUP0202253A3 (en) 2003-12-29
SK112002A3 (en) 2003-05-02
DE60032905D1 (de) 2007-02-22
US20050159445A1 (en) 2005-07-21
TR200200066T2 (tr) 2002-04-22
PE20010299A1 (es) 2001-03-07
US6566370B1 (en) 2003-05-20
MY133503A (en) 2007-11-30
NZ515616A (en) 2004-05-28
US20040192722A1 (en) 2004-09-30
AU773304B2 (en) 2004-05-20
CZ20014488A3 (cs) 2003-01-15
JP2003503449A (ja) 2003-01-28
HRP20020013A2 (en) 2003-08-31

Similar Documents

Publication Publication Date Title
IL146697A0 (en) SELECTIVE iGluR5 RECEPTOR FOR THE TREATMENT OF MIGRAINE
IL140325A0 (en) Ep4 receptor selective agonists in the treatment of osteoporosis
IL143979A0 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
ZA200109335B (en) Generation of therapeutic microfoam.
HUP0200079A3 (en) Treatment of infertility
IL136960A0 (en) Combination therapy for the treatment of migraine
HUP0200157A3 (en) Treatment of infertility
HU0001891D0 (en) Medicament for the treatment of migraine
IL136962A0 (en) Combination therapy for the treatment of migraine
AU2504101A (en) Device for carrying out the oscillation-induced selective treatment of malignantdiseases
IL136024A0 (en) Combination therapy for the treatment of migraine
GB0007811D0 (en) Method for the discontinuous thermal treatment of catalyst material
PL371270A1 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine
GB9924275D0 (en) Method for the treatment of obesity
TW375040U (en) Improved structure for the massaging apparatus
TW376677U (en) Device of mating-blockade for the pets
SI1147083T1 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
TW376691U (en) Structure of combination device for the flashing ornaments
GB9923551D0 (en) Treatment of neuropsychiatric disorders
GB9917448D0 (en) Bathing apparatus
TW383595U (en) Improvement for foot-sole massager
GB9916945D0 (en) Shower trough
AP2000001896A0 (en) Improved process for maintaining the stabillity of the fortification
IL143568A0 (en) Treatment of infertility
IL143729A0 (en) Treatment of infertility